Peptide derivatives as prodrugs.
The results quoted here suggest strongly that peptides as prodrugs are a real possibility for future forms of therapy. Pharmacokinetics and bioavailability are certainly altered by such modifications, usually in a positive sense. The possibilities in utilizing active transport permeases to direct drugs to the desired receptor are an obvious reality, and will undoubtedly lead to new methods for treating bacterial, fungal or even viral infections, and for improved ways of presenting anti-tumour agents. The number of patents appearing in this field is indicative of the interest shown in the pharmaceutical industry.
Thomas
W A
WA
D000596:Amino Acids; D000818:Animals; D001419:Bacteria / Q000378:metabolism; D001682:Biological Availability; D001693:Biological Transport, Active; D002707:Chlordiazepoxide / Q000031:analogs & derivatives* / Q000378:metabolism; D003975:Diazepam / Q000031:analogs & derivatives* / Q000378:metabolism; D005445:Flunitrazepam / Q000031:analogs & derivatives* / Q000378:metabolism; D005479:Flurazepam / Q000031:analogs & derivatives* / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D009567:Nitrazepam / Q000031:analogs & derivatives* / Q000378:metabolism; D010215:Papio; D051381:Rats
D000596:Amino Acids; D005445:Flunitrazepam; D002707:Chlordiazepoxide; D009567:Nitrazepam; D005479:Flurazepam; D003975:Diazepam